Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms. - Wikidata - awgldk - TriplyDB

Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms.

Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms.

http://www.wikidata.org/entity/Q43826855

about

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.

P2860

Q47556634-9A889012-956D-4ECB-839D-2EA0C8CD88A1

P2860

Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms.

http://www.wikidata.org/entity/Q43826855

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pioglitazone stabilizes athero ...... in AMPK-dependent mechanisms.

@en

Pioglitazone stabilizes athero ...... in AMPK-dependent mechanisms.

@nl

type

label

Pioglitazone stabilizes athero ...... in AMPK-dependent mechanisms.

@en

Pioglitazone stabilizes athero ...... in AMPK-dependent mechanisms.

@nl

prefLabel

Pioglitazone stabilizes athero ...... in AMPK-dependent mechanisms.

@en

Pioglitazone stabilizes athero ...... in AMPK-dependent mechanisms.

@nl

P1433

Q43826855-E185AEF1-0650-46E6-9F92-E0F4519A2E30

P1476

Q43826855-D492B854-9C0B-4D2D-8B37-FEAC8F6A20A7

P2093

Q43826855-1591C80E-100B-4EDD-B7A2-D0C62D94E9F9

Q43826855-1DABB3FF-C4B3-41D6-A568-11BEF5A50539

Q43826855-27E792E2-6AFB-4B64-9795-A5FFDBE4C345

Q43826855-28686EBD-2AB6-4BC3-A156-B29410FC88E0

Q43826855-2A85898B-FDF2-4416-AA9A-8F122772813C

Q43826855-5F9612EC-BA8B-4DE8-A775-5113F90BB9D4

Q43826855-6CE47EB7-66DF-4773-874E-51355A577DE8

Q43826855-70F064CB-BD8D-47EF-AF11-C88E6B9EA567

Q43826855-756DD051-BE27-4C5D-B649-81FCFDDCBA6E

Q43826855-A4199399-CC82-4E95-BACA-00EA8040DCBC

P2860

Q43826855-15753488-6197-4759-B25D-8282BE8FA646

Q43826855-18EB5EDC-7519-491B-AFBD-0A0D69C4A10B

Q43826855-1B936FFB-B7FA-428B-980E-0722BA5E0B56

Q43826855-1CE647A5-7360-426D-855A-4BD82A5D1A27

Q43826855-2C54EF62-9F05-4F8D-A8FC-769D76F3EC21

Q43826855-31D3C333-E38D-4461-9A51-19961F9DF597

Q43826855-3859DEEC-ACC8-4664-B94D-BBF6569D66C8

Q43826855-3D879543-2804-4449-9CC5-CAF8B07BF076

Q43826855-43561EEE-3C97-4B3D-8A50-21E9967EC79C

Q43826855-5B1A7764-9E1A-484F-9109-C50B2651652F

P2888

Q43826855-EEF9DE8F-B120-405E-B3D7-46E0D83BE919

P304

Q43826855-BF8C6897-71C8-4C43-9175-33EA6B123609

P31

Q43826855-D9BDE800-C590-4F7E-9BC7-454161B9DD32

P356

Q43826855-A7599F72-8E79-4F57-9F9B-9715F06FCC4C

P407

Q43826855-6EEAEA69-6FCA-4AC0-86A6-6C00185050B2

P433

Q43826855-183C125F-C750-444A-A097-8ADEF29C8B21

P478

Q43826855-DEA8707D-0657-48B1-AFAA-AA9B72DB6845

P50

Q43826855-A9ADD2DA-7D5F-4142-A735-8222DE28F447

P577

Q43826855-A02B45C8-3976-4353-A751-7283F4E449C8

P6179

Q43826855-D7DA0FC8-0B1F-4960-8C8D-D184F780F0FD

P698

Q43826855-801CAEC2-30F0-4A28-A2AA-B1C284681D54

P921

Q43826855-2B2575B5-81F4-4280-AE87-A0D6F8EA82F5

P932

Q43826855-2DB70880-4271-4EED-A757-C877E2A19470

P356

S12933-017-0623-6

P1433

Cardiovascular Diabetology

P1476

Pioglitazone stabilizes athero ...... e in AMPK-dependent mechanisms

@en

P2093

Hang Yu

http://www.w3.org/2001/XMLSchema#string

Jiahao Feng

http://www.w3.org/2001/XMLSchema#string

Juan Zhou

http://www.w3.org/2001/XMLSchema#string

Lijun Wang

http://www.w3.org/2001/XMLSchema#string

Lin Yang

http://www.w3.org/2001/XMLSchema#string

Tao Chen

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaojuan Fan

http://www.w3.org/2001/XMLSchema#string

Yan Wu

http://www.w3.org/2001/XMLSchema#string

Yanjie Yang

http://www.w3.org/2001/XMLSchema#string

P2860

AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling

AMP-activated protein kinase, stress responses and cardiovascular diseases

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Progress and challenges in translating the biology of atherosclerosis

Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice.

Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}.

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Transcriptional and epigenetic regulation of T-helper lineage specification.

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

P2888

s12933-017-0623-6

P304

140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12933-017-0623-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092450156

http://www.w3.org/2001/XMLSchema#string

P698

29084546

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

5663071

http://www.w3.org/2001/XMLSchema#string